BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang N, Gu J, Yin L, Wu J, Du MY, Ding K, Huang T, He X. Incorporation of alpha-fetoprotein(AFP) into subclassification of BCLC C stage hepatocellular carcinoma according to a 5-year survival analysis based on the SEER database. Oncotarget 2016;7:81389-401. [PMID: 27835609 DOI: 10.18632/oncotarget.13232] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 He C, Zhang Y, Cai Z, Lin X. The prognostic and predictive value of the combination of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma who receive transarterial chemoembolization therapy. Cancer Manag Res 2019;11:1391-400. [PMID: 30863150 DOI: 10.2147/CMAR.S190545] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
2 Luo HM, Zhao SZ, Li C, Chen LP. Preoperative platelet-albumin-bilirubin grades predict the prognosis of patients with hepatitis B virus-related hepatocellular carcinoma after liver resection: A retrospective study. Medicine (Baltimore). 2018;97:e0226. [PMID: 29561452 DOI: 10.1097/md.0000000000010226] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
3 Abdelghany AM, Rezk NS, Osman MM, Hamid AI, Al-Breedy AM, Abdelsattar HA. Using Lamin B1 mRNA for the early diagnosis of hepatocellular carcinoma: a cross-sectional diagnostic accuracy study. F1000Res 2018;7:1339. [PMID: 30467522 DOI: 10.12688/f1000research.14795.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Yoo JJ, Yu SJ, Lee B, Cho EJ, Lee JH, Kim SG, Kim YJ, Kim YS, Yoon JH. Appraisal of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma Classified as Barcelona Clinic Liver Cancer Stage B. Gut Liver 2020;14:377-86. [PMID: 31533399 DOI: 10.5009/gnl19112] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Yoo JJ, Chung GE, Lee JH, Nam JY, Chang Y, Lee JM, Lee DH, Kim HY, Cho EJ, Yu SJ, Kim YJ, Yoon JH; Seoul Liver Group. Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib. Cancer Res Treat 2018;50:366-73. [PMID: 28521494 DOI: 10.4143/crt.2017.126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
6 He C, Zhang Y, Lin X. Increased Overall Survival and Decreased Cancer-Specific Mortality in Patients with Hepatocellular Carcinoma Treated by Transarterial Chemoembolization and Human Adenovirus Type-5 Combination Therapy: a Competing Risk Analysis. J Gastrointest Surg 2018;22:989-97. [PMID: 29435900 DOI: 10.1007/s11605-018-3703-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
7 He CB, Lin XJ. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101. PLoS One 2017;12:e0174769. [PMID: 28355305 DOI: 10.1371/journal.pone.0174769] [Cited by in Crossref: 22] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
8 Chi X, Jiang L, Yuan Y, Huang X, Yang X, Hochwald S, Liu J, Huang H. A comparison of clinical pathologic characteristics between alpha-fetoprotein negative and positive hepatocellular carcinoma patients from Eastern and Southern China. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02279-w] [Reference Citation Analysis]
9 Han L, Wang Y, Huang X, Liu B, Hu L, Ma C, Liu J, Xue J, Qu W, Liu F, Feng F, Liu W. A stage-specific cancer chemotherapy strategy through flexible combination of reduction-activated charge-conversional core-shell nanoparticles. Theranostics 2019;9:6532-49. [PMID: 31588234 DOI: 10.7150/thno.35057] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
10 Zhang QQ, Wu PY, ALBahde M, Zhang LF, Zhou ZH, Liu H, Li YF, Wang WL. Do Elderly Patients With Stage I-II Hepatocellular Carcinoma Benefit From More Radical Surgeries? A Population-Based Analysis. Front Oncol 2020;10:479. [PMID: 32373517 DOI: 10.3389/fonc.2020.00479] [Reference Citation Analysis]
11 Zhang R, Zhang LJ, Yang ML, Huang LS, Chen G, Feng ZB. Potential role of microRNA‑223‑3p in the tumorigenesis of hepatocellular carcinoma: A comprehensive study based on data mining and bioinformatics. Mol Med Rep 2018;17:2211-28. [PMID: 29207133 DOI: 10.3892/mmr.2017.8167] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
12 Sternby Eilard M, Holmberg E, Naredi P, Söderdahl G, Rizell M. Addition of alfa fetoprotein to traditional criteria for hepatocellular carcinoma improves selection accuracy in liver transplantation. Scand J Gastroenterol 2018;53:976-83. [PMID: 30169974 DOI: 10.1080/00365521.2018.1488180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]